AU2010303343B2 - Purine derivatives useful as HSP90 inhibitors - Google Patents

Purine derivatives useful as HSP90 inhibitors Download PDF

Info

Publication number
AU2010303343B2
AU2010303343B2 AU2010303343A AU2010303343A AU2010303343B2 AU 2010303343 B2 AU2010303343 B2 AU 2010303343B2 AU 2010303343 A AU2010303343 A AU 2010303343A AU 2010303343 A AU2010303343 A AU 2010303343A AU 2010303343 B2 AU2010303343 B2 AU 2010303343B2
Authority
AU
Australia
Prior art keywords
amino
propyl
ethyl
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010303343A
Other languages
English (en)
Other versions
AU2010303343A1 (en
Inventor
Gabriela Chiosis
Weilin Sun
Tony Taldone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2010303343A1 publication Critical patent/AU2010303343A1/en
Priority to AU2013204109A priority Critical patent/AU2013204109B2/en
Priority to AU2013204899A priority patent/AU2013204899B2/en
Priority to AU2013204882A priority patent/AU2013204882B2/en
Priority to AU2013204891A priority patent/AU2013204891B2/en
Application granted granted Critical
Publication of AU2010303343B2 publication Critical patent/AU2010303343B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2010303343A 2009-10-07 2010-10-07 Purine derivatives useful as HSP90 inhibitors Ceased AU2010303343B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2013204109A AU2013204109B2 (en) 2009-10-07 2013-04-11 Purine derivatives useful as hsp90 inhibitors
AU2013204899A AU2013204899B2 (en) 2009-10-07 2013-04-12 Purine derivatives useful as hsp90 inhibitors
AU2013204882A AU2013204882B2 (en) 2009-10-07 2013-04-12 Purine derivatives useful as hsp90 inhibitors
AU2013204891A AU2013204891B2 (en) 2009-10-07 2013-04-12 Purine derivatives useful as hsp90 inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24934909P 2009-10-07 2009-10-07
US61/249,349 2009-10-07
PCT/US2010/051872 WO2011044394A1 (en) 2009-10-07 2010-10-07 Purine derivatives useful as hsp90 inhibitors

Related Child Applications (4)

Application Number Title Priority Date Filing Date
AU2013204109A Division AU2013204109B2 (en) 2009-10-07 2013-04-11 Purine derivatives useful as hsp90 inhibitors
AU2013204891A Division AU2013204891B2 (en) 2009-10-07 2013-04-12 Purine derivatives useful as hsp90 inhibitors
AU2013204882A Division AU2013204882B2 (en) 2009-10-07 2013-04-12 Purine derivatives useful as hsp90 inhibitors
AU2013204899A Division AU2013204899B2 (en) 2009-10-07 2013-04-12 Purine derivatives useful as hsp90 inhibitors

Publications (2)

Publication Number Publication Date
AU2010303343A1 AU2010303343A1 (en) 2012-04-19
AU2010303343B2 true AU2010303343B2 (en) 2015-11-19

Family

ID=43857159

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010303343A Ceased AU2010303343B2 (en) 2009-10-07 2010-10-07 Purine derivatives useful as HSP90 inhibitors

Country Status (16)

Country Link
US (2) US9328114B2 (https=)
EP (2) EP3091019B1 (https=)
JP (3) JP5941407B2 (https=)
KR (2) KR101906568B1 (https=)
CN (3) CN106083855B (https=)
AU (1) AU2010303343B2 (https=)
BR (1) BR112012008019A2 (https=)
CA (1) CA2776308C (https=)
DK (1) DK2486039T3 (https=)
EA (1) EA029272B1 (https=)
ES (2) ES2733131T3 (https=)
LT (1) LT2486039T (https=)
MX (1) MX340714B (https=)
NZ (2) NZ599138A (https=)
PT (1) PT2486039T (https=)
WO (1) WO2011044394A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2008005937A2 (en) 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
JP5941407B2 (ja) 2009-10-07 2016-06-29 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害剤
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
JP6266506B2 (ja) 2011-04-05 2018-01-24 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害物質
EA201490230A1 (ru) * 2011-07-08 2014-06-30 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Применение меченых ингибиторов hsp90
EP2972394A4 (en) 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer HSP90-DESIGNING AND THERAPY
SG11201601542SA (en) 2013-08-16 2016-04-28 Sloan Kettering Inst Cancer Selective grp94 inhibitors and uses thereof
BR112016005199B1 (pt) 2013-08-23 2022-02-22 Neupharma, Inc Certos compostos químicos, composições, e métodos
WO2015138039A1 (en) 2013-12-23 2015-09-17 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
MX387627B (es) * 2014-09-17 2025-03-18 Memorial Sloan Kettering Cancer Center Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia
US20180280397A1 (en) 2015-10-05 2018-10-04 Memorial Sloan Kettering Cancer Center Rational combination therapy for the treatment of cancer
WO2018035061A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
KR20190138871A (ko) * 2017-04-24 2019-12-16 사무스 테라퓨틱스, 인코포레이티드 Hsp90 저해제 경구 제형 및 관련 방법
CN111683658A (zh) * 2017-06-23 2020-09-18 萨缪斯治疗股份有限公司 用于创伤性脑损伤及其后遗症的多蛋白复合物抑制剂疗法
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025099111A1 (en) 2023-11-10 2025-05-15 Wella Germany Gmbh New telescoping syntheses of 6-hydroxy-benzomorpholine (3,4-dihydro-2h-1,4-benzoxazin-6-ol)
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005937A2 (en) * 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
WO2008115719A1 (en) * 2007-03-20 2008-09-25 Curis, Inc. Fused amino pyridine as hsp90 inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2287387C (en) 1997-05-14 2010-02-16 Sloan-Kettering Institute For Cancer Research Methods and compositions for destruction of selected proteins
JP2002541255A (ja) 1999-04-09 2002-12-03 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｅｒ族チロシンキナーゼの分解および／または阻害方法および組成物
US7439359B2 (en) 2000-11-02 2008-10-21 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
WO2003037860A2 (en) * 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
NL1019258C2 (nl) * 2001-10-30 2003-05-02 Iku Holding Montfoort Bv Bevestigingsconstructie, in het bijzonder voor een buitenspiegel van een motorvoertuig.
EP1450784A4 (en) 2001-11-09 2005-02-09 Conforma Therapeutics Corp HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE
CN1649866A (zh) 2002-02-28 2005-08-03 阿斯特拉曾尼卡有限公司 3－环状基－5－(含氮5－元环)甲基－噁唑烷酮衍生物及其作为抗菌药物的用途
EP1620564A4 (en) 2003-04-18 2008-03-12 Cytovia Inc METHOD FOR TREATING DISEASES RESPONSING TO APOPTOSIS INDUCTION AND SCREENING TESTS
MXPA06002997A (es) 2003-09-18 2007-02-08 Conforma Therapeutics Corp Novedosos compuestos heterociclicos como inhibidores- hsp90.
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
EP1913738A2 (en) 2005-07-27 2008-04-23 QUALCOMM Incorporated System and method for forward link only messages
WO2007134298A2 (en) * 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
WO2007143629A1 (en) 2006-06-02 2007-12-13 Nexgenix Pharmaceuticals Treatment of neurofibromatosis with inhibitors of a signal transduction pathway
US20080053862A1 (en) 2006-06-30 2008-03-06 Sanford, L.P. Interlocking Nestable Article Holder
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
WO2009007399A1 (en) * 2007-07-12 2009-01-15 Crystax Pharmaceuticals, S.L. New compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
NZ586129A (en) 2007-11-14 2012-06-29 Myrexis Inc Therapeutic compounds and their use in treating diseases and disorders
JP5941407B2 (ja) 2009-10-07 2016-06-29 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害剤
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
JP6266506B2 (ja) 2011-04-05 2018-01-24 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害物質
SG11201601542SA (en) 2013-08-16 2016-04-28 Sloan Kettering Inst Cancer Selective grp94 inhibitors and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005937A2 (en) * 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
WO2008115719A1 (en) * 2007-03-20 2008-09-25 Curis, Inc. Fused amino pyridine as hsp90 inhibitors

Also Published As

Publication number Publication date
US10172863B2 (en) 2019-01-08
CN106083855A (zh) 2016-11-09
CN106083855B (zh) 2020-04-10
CN102639534A (zh) 2012-08-15
CA2776308C (en) 2020-01-28
JP5941407B2 (ja) 2016-06-29
LT2486039T (lt) 2016-10-10
JP6804483B2 (ja) 2020-12-23
NZ625593A (en) 2016-03-31
ES2733131T3 (es) 2019-11-27
KR20120083898A (ko) 2012-07-26
WO2011044394A1 (en) 2011-04-14
US20120208806A1 (en) 2012-08-16
US9328114B2 (en) 2016-05-03
KR20180112117A (ko) 2018-10-11
US20160310497A1 (en) 2016-10-27
MX2012004089A (es) 2012-08-23
BR112012008019A2 (pt) 2016-03-01
EP2486039B1 (en) 2016-06-01
AU2010303343A1 (en) 2012-04-19
JP2013507381A (ja) 2013-03-04
EP3091019B1 (en) 2019-04-03
DK2486039T3 (en) 2016-09-12
EP3091019A3 (en) 2017-01-18
KR102129420B1 (ko) 2020-07-03
EP3091019A2 (en) 2016-11-09
EP2486039A4 (en) 2012-08-15
PT2486039T (pt) 2016-09-06
EP2486039A1 (en) 2012-08-15
JP2016145262A (ja) 2016-08-12
EA201270535A1 (ru) 2012-09-28
CN105924443A (zh) 2016-09-07
ES2589403T3 (es) 2016-11-14
CA2776308A1 (en) 2011-04-14
EA029272B1 (ru) 2018-03-30
KR101906568B1 (ko) 2018-10-10
MX340714B (es) 2016-07-22
NZ599138A (en) 2014-06-27
JP2018104451A (ja) 2018-07-05
JP6326088B2 (ja) 2018-05-16

Similar Documents

Publication Publication Date Title
AU2010303343B2 (en) Purine derivatives useful as HSP90 inhibitors
KR102010222B1 (ko) Ｈｓｐ９０ 억제제
GB2244487A (en) Azple derivatives
CA2705579A1 (en) Therapeutic compounds and their use in treating diseases and disorders
AU2013204109B2 (en) Purine derivatives useful as hsp90 inhibitors
HK1230612A (en) Purine derivatives useful as hsp90 inhibitors
HK1230612A1 (en) Purine derivatives useful as hsp90 inhibitors
NZ616758B2 (en) Hsp90 inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired